NTLA

Intellia Therapeutics, Inc

10.59

USD

NTLA Earnings Reports

Positive Surprise Ratio

NTLA beat 21 of 39 last estimates.

54%

Next Report

Date of Next Report

Feb 25, 2026

Estimate for Q4 25 (Revenue/ EPS)

$13.04M

-$0.97

Implied change from Q3 25 (Revenue/ EPS)

-5.36%

+5.43%

Implied change from Q4 24 (Revenue/ EPS)

+1.31%

-23.62%

Intellia Therapeutics, Inc earnings per share and revenue

On Nov 06, 2025, NTLA reported earnings of -0.92 USD per share (EPS) for Q3 25, beating the estimate of -1.02 USD, resulting in a 9.97% surprise. Revenue reached 13.78 million, compared to an expected 15.49 million, with a -11.02% difference. The market reacted with a -22.73% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 23 analysts forecast an EPS of -0.97 USD, with revenue projected to reach 13.04 million USD, implying an increase of 5.43% EPS, and decrease of -5.36% in Revenue from the last quarter.

FAQ

What were Intellia Therapeutics, Inc's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Intellia Therapeutics, Inc reported EPS of -$0.92, beating estimates by 9.97%, and revenue of $13.78M, -11.02% below expectations.

How did the market react to Intellia Therapeutics, Inc's Q3 2025 earnings?

The stock price moved down -22.73%, changed from $12.32 before the earnings release to $9.52 the day after.

When is Intellia Therapeutics, Inc expected to report next?

The next earning report is scheduled for Feb 25, 2026.

What are the forecasts for Intellia Therapeutics, Inc's next earnings report?

Based on 23 analysts, Intellia Therapeutics, Inc is expected to report EPS of -$0.97 and revenue of $13.04M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.